Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Although several studies indicate that ALDH
2024-12-12

Although several studies indicate that ALDH2 protects the heart from injury and maladaptive remodeling (reviewed in [11], [12], [13]), accumulating evidence indicates that deficiency of the enzyme could be protective as well. For example, mice expressing the defective Aldh2*2 mutation show lower ald
-
4-ap Perhaps the discovery of this linkage has served
2024-12-12

Perhaps the discovery of this linkage has served to catapult much of the work on ABCA1, leaving its family member in need of a relationship with a defined human pathology. In this regard, there is by now a quite mature literature that suggests that ABCA2 may have been overlooked in terms of its impo
-
br Conflicts of interest br Newly Identified Mechanisms
2024-12-12

Conflicts of interest Newly Identified Mechanisms of APN Resistance Hold Therapeutic Potential APN, APN Receptors, and APN Cardiovascular Protection APN Resistance in Cardiovascular Disease The Molecular Mechanisms of APN Resistance Concluding Remarks and Future Directions Finally,
-
Does dietary caffeine interfere with
2024-12-12

(8) Does dietary caffeine interfere with antinociception by other modalities that alter pain (TENS, exercise, joint mobilization, water immersion therapy)? Caffeine and/or A1R antagonists inhibit antinociception by each of these modalities in preclinical studies, such that there is potential for int
-
br New AMPK activators Fenofibrate is a drug of the
2024-12-12

New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu
-
apoptosis To understand the kinase selectivity profile of th
2024-12-12

To understand the kinase selectivity profile of this series, apoptosis , as a representative analog from this series, was profiled against 216 purified protein kinases representing the tyrosine and serine/threonine kinase families using an in-house Caliper EZ Reader mobility shift assay. Assays wer
-
br The MIR The MIR
2024-12-12

The MIR The MIR is defined by the ability of a single rat mAb to muscle or electric organ AChRs, typically mAb 35, to block binding of half or more of autoantibodies in human MG or EAMG [44], [45], [46]. Antibodies to the MIR are pathologically significant because they exhibit all the major patho
-
Investigating these possibilities will illuminate whether ce
2024-12-12

Investigating these possibilities will illuminate whether Probenecid possess mechanisms to differentially detect ACLY-generated versus ACSS2-generated acetyl-CoA as well as define the functional relationship between histone acetylation levels and cellular functions and phenotypes. Given that ACLY d
-
The MOB and AOB are
2024-12-11

The MOB and AOB are important in ungulates (Keller and Levy, 2012, Sanchez-Andrade and Kendrick, 2009), which rely heavily on odorant information for social interactions (Baum and Cherry, 2015, Keller and Levy, 2012, Osada et al., 2014, Villagran and Ungerfeld, 2013). The release of GABA and glutama
-
br Introduction AMPA receptors AMPARs mediate the majority
2024-12-11

Introduction AMPA receptors (AMPARs) mediate the majority of fast excitatory postsynaptic currents (EPSCs) in the bosentan (Jonas, 2000). The brevity of EPSCs and rapid deactivation of AMPARs depend upon a short lifetime of synaptically released glutamate, estimated to be about 1 ms (Clements et
-
Heart failure is a chronic syndrome in which the heart
2024-12-11

Heart failure is a chronic syndrome in which the heart is unable of pumping an adequate supply of blood to meet the metabolic requirements of the body or generating the required elevated ventricular filling pressures to maintain output [34]. Despite considerable advances in the treatment of heart fa
-
ABT 702 dihydrochloride Further examination of these vmat IR
2024-12-11

Further examination of these vmat-IR cells shows that they are also positive for vimentin (vim-IR) (Fig. 3A). However, within any one cell there may be a region of weaker vmat-IR, suggesting sub-cellular localization. As also shown in Fig. 3B and C not all vim-IR cells are vmat-IR suggesting that th
-
br Conclusion br Conflicts of interest br Introduction
2024-12-10

Conclusion Conflicts of interest Introduction Enzymes are widely applied as biocatalysts in fields such as synthetic chemistry [1], pharmaceuticals [2], environmental treatment [3], and food technology [4] because they can catalyze chemical transformations in a highly selective manner under
-
br Materials and methods br Results The
2024-12-10

Materials and methods Results The determination of the intrinsic inhibitory potential of the oximes HI-6 and MMB-4 with human and guinea pig AChE revealed marked differences between both oximes (Table 1). MMB-4 had an only marginal effect on both AChE species, calculated IC50 of >1000μM, whil
-
It has been recognized for decades that
2024-12-10

It has been recognized for decades that neurons in the mammalian central nervous system may release both a fast-acting, typically amino acid derived neurotransmitter such as glutamate or GABA, and a second peptidergic neuromodulatory molecule such as neuropeptide Y, substance P, or cholecystokinin.
15826 records 41/1056 page Previous Next First page 上5页 4142434445 下5页 Last page